Sipuleucel-T (Provenge®)—Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention

Cost-Effectiveness Analysis of Abiraterone and Sipuleucel-T in Asymptomatic Metastatic Castration-Resistant Prostate Cancer

(2017) Cynthia L. Gong et al.   Journal of the National Comprehensive Cancer Network

Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities

(2012) Heather Payne et al.   BJU INTERNATIONAL

Rationing in urologic oncology: Lessons from sipuleucel-T for advanced prostate cancer

(2012) Jeffrey Peppercorn et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Sipuleucel-T for the treatment of metastatic prostate cancer

(2012) Channing J. Paller et al.   Human Vaccines & Immunotherapeutics

Pharmaco-economic aspects of Sipuleucel-T

(2012) Steven Simoens   Human Vaccines & Immunotherapeutics

Cancer vaccines and immunotherapeutics

(2012) Bengt Jönsson et al.   Human Vaccines & Immunotherapeutics

Provenge: Revolutionary technology or ethical bust?

(2011) Justin B. Dickerson   Human vaccines & immunotherapeutics

Concerns About Provenge Simmer as CMS Ponders Coverage

(2011) M. Goozner   JNCI-Journal of the National Cancer Institute

Recent advances in the therapy of castration-resistant prostate cancer: The price of progress

(2011) Dhwanishiva Vasani et al.   MATURITAS

Listening to Provenge — What a Costly Cancer Treatment Says about Future Medicare Policy

(2011) James D. Chambers et al.   NEW ENGLAND JOURNAL OF MEDICINE

Citizenship in Our Profession

(2010) Michael J. Droller   JOURNAL OF UROLOGY

Landmark approval for Dendreon's cancer vaccine

(2010) Laura DeFrancesco   NATURE BIOTECHNOLOGY